acquir ipipelin
symc acquisit expand enterpris secur
follow-up slash estim price near-
term liquid issu debt burden concern
open field address unmet need ovarian cancer
cusp fulli commercialwhat hold back
headwind n-t opportun l-t initi outperform
blossom beyond baylor -- multitaa readi first multi-
updat bridg better formul
offer earli read dri cell therapi program look
uptick busi develop
formal pass financ signal confid
restructur place control op ex spend pivot away
burn reset pt
analyst certif import disclosur see
firdaps post strong quarter look forward musk-mg
data
notch higher acut spin rais pt
strong book settlement doj practic fusion
strong number excit setup deal
report pdgm off-set develop
focu shift high-margin consum divis enterpris
sold
updat model worldpay merger
first look reflect weaken econom shift
spin-off analysi underway begin unlock sub valu
overhang stock
datatim august confer takeaway earn
mix quarter expect target hm revenu growth
sale market leverag drive solid profit full
doubl
compel lower pt
busi usual strong quarter damag
bear case reiter outperform
back fray
strong quarter ahead expect
brace impact mobil declin
strong result ration capac plan maintain
cpst foundat growth place
rais pt growth continu
strong collect effici execut
ka ching anoth quarter steadi dividend coverag
solid quarter also small continu recommend
acquir ipipelin
roper announc agreement acquir ipipelin thoma bravo approxim consist
deal fund transact cash/revolv expect close ipipelin join immedi cash
accret expect revenu tax associ financ cost
ipipelin provid cloud-bas solut afford saa applic life insur annuiti industri across
broad network approxim carrier distributor agent product streamlin
vertic tier channel layer underwrit ultim policyhold workflow autom standard
also facilit third-parti inform tax medic etc regulatori complianc state state feder
symc acquisit expand enterpris secur
announc intent acquir symantec enterpris secur busi all-cash transact expect
close pend regulatori approv us/eu/japan deal unlik catch investor guard
long rumor consist avgo strategi use acceler revenue/eps/fcf growth
mitig cycl volatil pivot combin silicon softwar expect increment
top-line ebitda realiz run-rat synergi exit depend time
synergies/debt paydown see deal ad eps/fcf like accret deal
continu expans high-margin softwar reiter outperform
cloud
follow-up slash estim price near-term liquid issu debt burden
normal revenu sequenti take account one-tim item vs
print weak margin need focu execut next two year given restrict coven
revolv make acquisit like sell fiber/datacenter/cloud infrastructur asset rais
de-lever still believ neutral provid last mile access enterpris
uniqu posit competition/pr clearli ratchet recess major risk churn increas key
ramp new hire sale forc increas product lower pt lower est
open field address unmet need ovarian cancer
host key opinion leader treatment gynecolog oncolog dr premal thaker discuss
ovarian cancer treatment landscap better understand emerg therapi develop call walk
pervas late-stag diagnosi coupl treatment paradigm either began incorpor new
treatment modal remain unmet need respect durabl clinic remiss current soc
despit approv commerci parp inhibitor olaparib niraparib rucaparib therapi gener
mutation-specif serv ovarian cancer popul broadli call cover emerg therapeut
celsion whose use combin neoadjuv chemotherapi surgic debulk could transform
treatment paradigm patient high unmet need
cusp fulli commercialwhat hold back share
net loss vs estimate import expect begin gener sale
three product enabl success complet manufactur regulatori turnaround bivigam
launch later month briskli grow supply-constrain ivig market asceniv entri track earli
season rsv rate begin climb project revenu respect multipl
sale conserv view would impli valuat share sell sinc april continu
view deepli under-valued biopharma play anticip transit full commerci statu revenu
growth drive stock out-performance
report adjust ep line estim penni higher consensu estim
total revenu adjust ep continu grow faster y/i growth guidanc organ growth
strong vs estim compani guid organ growth though
surpris us given strong activ emphas preview current estim
organ growth would full year leverag question would linger stock
near term thesi rest lt growth trajectori compani
headwind n-t opportun l-t initi outperform rate
initi coverag lovesac stock rate outperform price target
past sever month work aggress enhanc expand consum growth e-commerce coverag
focu upon compani use digit technolog connect better consum improv oper disciplin
view still earli stage process brand develop lovesac endeavor disrupt larg
somewhat tire home-furnish marketplac uniqu product offer tech-driven distribut infrastructur
tariff-rel headwind could impact result weigh upon share near-term analysi impli market
meaning underappreci long-term sale profit potenti
blossom beyond baylor -- multitaa readi first multi-cent trial
thursday marker announc earn discuss recent progress manag view
unfairli punish sinc juli present earlybut view encouragingdata baylor on-going trial
multitaa pancreat cancer data includ one complet respons metastat patient extrem rare occurr
chemotherapi alon believ patient investor may reward fresh data one on-going baylor-
sponsor trial decemb januari includ updat result aml main value-driv program compani
believ marker track initi first company-sponsor trial aml second company-sponsor trial
could begin reiter outperform pt
updat bridg better formul
thursday report earn provid corpor updat wake mix data pku program
believ fell short clinic proof-of-concept compani face critic near-term catalyst form phase
result cirrhot patient hyperammonemia come minimum believ
reduct serum ammonia must demonstr justifi develop patient cirrhosi and/or urea cycl
disord pku manag recogn need safe administ higher dose achiev meaning
reduct serum phenylalanin recent initi bridg studi healthi volunt test new lyophil
formul reiter outperform rate pt
offer earli read dri cell therapi program look uptick busi develop
present financi result provid preview opregen data present american
academi ophthalmolog meet octob specif plan present data long term
follow-up month patient dose manual inject advers event profil one patient
dose use orbit sd devic deliveri opregen rpe cell therapi manag expect complet dose
six patient orbit devic end posit month follow-up
six patient arvo meet may continu view potenti arvo dataset first true assess
formal pass financ signal confid close partnership
cdtx report unev result current cash balanc adequ fund oper
view compani need access addit capit complet phase develop rezafungin treatment
candidemia invas candidiasi ic expect earlier week cdtx formal notifi investor
financ compani would consumm tranch term agreement expect cdtx fulli
explor opportun partner rezafungin certain jurisdict outsid us revisit option financ
potenti issuanc equiti separ late juli cdtx began ind enabl studi lead antivir fc-conjug avc
long-act anti-vir prevent and/or treatment influenza
restructur place control op ex spend pivot away burn reset pt
present financi result believ new manag effect provid better
transpar metric commerci uptak skint rational target sale effort acut chronic
wound timelin re-engag burn market follow employe reduct manag believ cash runway
support busi least month estim top line data pilot studi skint
push month dfu vlu result modest reduct revenu
forecast also remov osteot revenu model net ep decreas
respect
firdaps post strong quarter look forward musk-mg data
firdaps net sale best consensu est resp reflect solid earli launch
execut prior pt transit firdaps note ramp moder organ
penetr treatment-na lem segment becom major sourc growth initi indic near-
term share out-performance may mute given market focu around launch trajectori believ attent soon shift
firdaps opportun musk-mg spa-phas data report see us sale
potenti ruzurgi view today report evid recent approv agent pose neglig
risk firdaps commerci prospect reiter op pt
notch higher acut spin rais pt
report revenu y/i well our/consensu estim rais
full-year guidanc adj ebitda margin y/i increas
full-yr guidanc alongsid strong result previous intim
manag announc intent spin acut segment separ public compani action
believ would facilit least two object pure-play oper busi valu may garner better market
recognit would protect iv meloxicam/pipelin control valu retent ahead potenti
reiter outperform rate increas price target
vlrx sale y/i line estimate/guid us target account total/new prescript
growth acceler grow y/i vs respect overal total prescript grew non-target
account declin slightli better trend partial off-set gm/opex line high end sale guidanc
brought slightli y/i midpoint lower net price stronger volum off-set
follow numer managed-car win manag see better y/i price trend vs moreov
volum driver placeimprov formulari posit expand us salesforc fulli integr v-go care program
manag reiter expect revenu growth rate acceler throughout y/i
strong book settlement doj practic fusion investig like
allscript report book ahead estim vs estim revenu came lower
end guidanc miss estim due longer anticip implement timelin lift book
full year provid visibl number despit revenue miss sever posit newsflow quarter
appeas investor management announc two new sunris client two paragon expans extens note advanc
stage negoti northwel doj investig practic fusion like settl fine
end overhang issu base time magnitud fine might requir compani seek
strong number excit setup deal convers
beat our/consensu vs strong contribut pretti much segment lift
number servic segment grew organ sinfoniarx grow softwar mix qtr
revenu continu grow impress vendor shift product segment sinfoniarx growth increas leverag
come prescribewel push gross margin higher expect step toward lt goal
pipelin remain strong manag medicaid commerci health plan expect see convers
especi recent restructur sale organ posit result emtm pilot pipelin commentari
traction recent acquisit make us excit growth sustain reiter outperform target
report pdgm off-set develop
report adj ep vs opco/street consensu adj result exclud
afam/acquisit cost relat closures/relocations/consolid post-quart re-affirmed
ep guidanc industri continu lobbi washington manag increasingli
confid off-set behavior cut follow quarter rais ep estim
price target
focu shift high-margin consum divis enterpris sold
symc deliv strong result best consensu estim revenu vs ep vs
cfo takeaway includ sell lower-margin highli volatil enterpris divis
after-tax proce return holder via special dividend post deal closur quarterli
dividend rais follow deal complet focu shift steadi low single-digit consum
busi expect gener margin annual ep
restructur also fund sale real estat underutil asset perform
updat model worldpay merger
supplement note updat model includ worldpay extend estim
estim ep includ five month worldpay ep estim respect
modestli prior pro forma estim decreas pro forma estim reflect
higher share count somewhat modest oper assumpt manag expect ep accret
previous expect dilut base accret expect organ revenu growth
gradual acceler estim organ growth acceler synergi ramp valuat
remain attract ep reiter outperform rate price target
first look reflect weaken econom shift
ftch report solid top-lin growth howev platform order contribut profit ebitda street estim
meanwhil fy revenu guidanc lower modestli street estim ebitda also guid lower higher
promot spend loyalti expect persist sever quarter
platform gmv opco/street estim y/i vs y/i platform servic revenu y/i vs
 platform fulfil revenu y/i vs brown activ custom
vs y/i aov flat y/i sequenti total revenu y/i opco/street
platform order contribut opco street management note weaker unit econom mostli increas price
promot smaller impact inventori write-down access loyalti digit paid media spend ebitda
opco/street cog opco d/g opco forecast
guidanc suggest platform gmv y/i opco/street total gmv y/i acquisit
new guard ad increment gmv ebitda street net
ratabl recogn ebitda benefit new guard organ miss larger
new guard acquisit close ftch paid cash/stock suggest ttm sale new guard first six
month sale y/i ftch management highlight synergi along profit dynam ebitda
spin-off analysi underway begin unlock sub valueoverhang stock
rais target maintain outperform rate increas stock partial off-set lower
target valu angi import take-away disclosur around formal evalu and/or angi posit
